Literature DB >> 15971272

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.

Malgorzata Kisielow1, Jan Kisielow, Giuseppina Capoferri-Sollami, Klaus Karjalainen.   

Abstract

Lymphocyte activation gene 3 (LAG-3/CD223) is a CD4 homolog known to be selectively expressed in activated T and NK cells. It is thought to have a negative regulatory function in T cells. With the help of new monoclonal antibodies against mouse LAG-3, we show that LAG-3 surface expression is not limited to activated T and NK cells but is also found on activated B cells. Induction of B cell surface expression is T cell dependent and mediated by a soluble factor. The majority of LAG-3 on B cell surface is endogenously produced, even though soluble LAG-3 is present in the culture supernatants and can be passively absorbed. As B cells express LAG-3 in a T cell dependent manner and not when activated by Toll-like-receptor agonists alone, we propose LAG-3 as a new marker of T cell induced B cell activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15971272     DOI: 10.1002/eji.200526090

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  84 in total

Review 1.  Update on hepatitis C virus-specific immunity.

Authors:  Donatella Ciuffreda; Arthur Y Kim
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

Review 2.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

Review 3.  Programmed death-1 checkpoint blockade in acute myeloid leukemia.

Authors:  Alison Sehgal; Theresa L Whiteside; Michael Boyiadzis
Journal:  Expert Opin Biol Ther       Date:  2015-06-03       Impact factor: 4.388

Review 4.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

5.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

Review 6.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 7.  The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity.

Authors:  David R Gibb; Sheinei J Saleem; Natalia S Chaimowitz; Joel Mathews; Daniel H Conrad
Journal:  Mol Immunol       Date:  2011-01-13       Impact factor: 4.407

Review 8.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

10.  LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.

Authors:  Kevin D Cook; Jason K Whitmire
Journal:  J Immunol       Date:  2016-05-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.